Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Onxeo acquires DNA Therapeutics
AsiDNA breaks the cycle of tumor DNA repair to speed up cancer cell death. DNA Therapeutics was acquired for an upfront payment of €1.7m paid at closing by
AsiDNA breaks the cycle of tumor DNA repair to speed up cancer cell death. DNA Therapeutics was acquired for an upfront payment of €1.7m paid at closing by
Earlier this year, AHF filed a federal lawsuit against Gilead Sciences and two other defendants in U.S. District Court, Northern District of California. It alleged drug patent manipulation
The designation gives the company 10 years of marketing exclusivity in European Union member countries if the product is approved. Oxigene president and CEO William Schwieterman said: "This
Praluent is a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor indicated as adjunct to diet and maximally tolerated statin therapy to treat adults with heterozygous familial hypercholesterolemia (HeFH)
Under the development and license deal, Cadila will carry out a phase III program in India and is granted an exclusive license to commercialize BUPI in India and
Gilead has been accused of infringing on patents Merck filed over a decade ago. Merck is seeking billions in damages and royalties on sales of Gilead’s two hepatitis
Taltz, which is administered as an injection, is indicated for patients who are candidates for systemic therapy or phototherapy. It is a humanized IgG4 monoclonal antibody that selectively
The move is part of a new initiative to counter the disease. Researchers expect to deliver results in 18 months, working with a smallpox virus derivative that may
The drug, however, did not show enough benefit in related inattention and mood complications. Pegvaliase is being tested against a placebo in patients of Phenylketonuria (PKU) or phenylalanine
The decision follows the submission of new evidence on the drug’s benefits. Last December, the agency turned down Zytiga for patients whose chemotherapy is not yet indicated after